Literature DB >> 24618732

Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation.

L Wang1, A Howarth2, R E Clark2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24618732     DOI： 10.1038/leu.2014.99

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  The biology of CML blast crisis.

Authors:  Bruno Calabretta; Danilo Perrotti
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

2.  Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.

Authors:  Sami Joha; Véronique Dauphin; Frédéric Leprêtre; Sélim Corm; Franck E Nicolini; Christophe Roumier; Olivier Nibourel; Nathalie Grardel; Véronique Maguer-Satta; Thierry Idziorek; Martin Figeac; Jean-Luc Laï; Bruno Quesnel; Gabriel Etienne; François Guilhot; Eric Lippert; Claude Preudhomme; Catherine Roche-Lestienne
Journal:  Leuk Res       Date:  2010-08-03       Impact factor: 3.156

3.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

4.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

5.  Regulator of myeloid differentiation and function: The secret life of Ikaros.

Authors:  Olivia L Francis; Jonathon L Payne; Rui-Jun Su; Kimberly J Payne
Journal:  World J Biol Chem       Date:  2011-06-26

6.  Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.

Authors:  Giovanni Cazzaniga; Frederik W van Delft; Luca Lo Nigro; Anthony M Ford; Joannah Score; Ilaria Iacobucci; Elena Mirabile; Mary Taj; Susan M Colman; Andrea Biondi; Mel Greaves
Journal:  Blood       Date:  2011-09-29       Impact factor: 22.113

7.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

8.  A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.

Authors:  Sebastian Francis; Claire Lucas; Steven Lane; Lihui Wang; Sarah Watmough; Katy Knight; Jo Bell; Mohammed Kaleel-Rahman; Edwin Lee; David O'Brien; Nauman M Butt; Walid Sadik; Lally De Soysa; Jim R C Seale; Rahuman Salim; Richard E Clark
Journal:  Leuk Res       Date:  2013-04-22       Impact factor: 3.156

9.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

10.  Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).

Authors:  Ilaria Iacobucci; Clelia Tiziana Storlazzi; Daniela Cilloni; Annalisa Lonetti; Emanuela Ottaviani; Simona Soverini; Annalisa Astolfi; Sabina Chiaretti; Antonella Vitale; Francesca Messa; Luciana Impera; Carmen Baldazzi; Pietro D'Addabbo; Cristina Papayannidis; Angelo Lonoce; Sabrina Colarossi; Marco Vignetti; Pier Paolo Piccaluga; Stefania Paolini; Domenico Russo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Robin Foà; Giovanni Martinelli
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113
View more
  4 in total

1.  Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Authors:  Y Dong; F Liu; C Wu; S Li; X Zhao; P Zhang; J Jiao; X Yu; Y Ji; M Zhang
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

2.  Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Jonathon L Payne; Chunhua Song; Yali Ding; Pavan Kumar Dhanyamraju; Yevgeniya Bamme; Joseph W Schramm; Dhimant Desai; Arati Sharma; Chandrika Gowda; Sinisa Dovat
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

Review 3.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

4.  Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.

Authors:  Neetu Singh; Anil Kumar Tripathi; Dinesh Kumar Sahu; Archana Mishra; Margaret Linan; Bianca Argente; Julia Varkey; Niranjan Parida; Rebecca Chowdhry; Hari Shyam; Nawazish Alam; Shivani Dixit; Pratap Shankar; Abhishek Mishra; Avinash Agarwal; Chris Yoo; Madan Lal Brahma Bhatt; Ravi Kant
Journal:  Oncotarget       Date:  2018-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.